Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT05430204 for Gestational Diabetes is completed. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Continuous Glucose Monitoring for Screening for Diabetes in Pregnancy 1,628
Clinical Trial NCT05430204 was an interventional study for Gestational Diabetes that is now completed. The study started on March 7, 2023, with plans to enroll 1,628 participants. Led by The University of Texas Health Science Center, Houston, the expected completion date was September 16, 2024. The latest data from ClinicalTrials.gov was last updated on December 4, 2025.
Brief Summary
The purpose of this study is to evaluate whether Continuous glucose monitoring (CGM) for diagnosis of gestational diabetes mellitus (GDM) improves maternal and neonatal outcomes related to GDM and to evaluate whether CGM for GDM diagnosis reduces the health system costs for mother-infant dyads compared to usual care
Official Title
Continuous Glucose Monitoring for Screening for Diabetes in Pregnancy:A Comparative Effectiveness Randomized Control Trial (PRECISE)
Conditions
Gestational DiabetesPublications
Scientific articles and research papers published about this clinical trial:Other Study IDs
- HSC-MS-22-0153
NCT ID Number
Start Date (Actual)
2023-03-07
Last Update Posted
2025-12-04
Completion Date (Estimated)
2024-09-16
Enrollment (Estimated)
1,628
Study Type
Interventional
PHASE
N/A
Status
Completed
Primary Purpose
Diagnostic
Design Allocation
Randomized
Interventional Model
Parallel
Masking
Single
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
Active Comparatorone-hour Glucose tolerance test (GCT) | Group 1: one-hour GCT Group I will be comprised of one-hour 50g glucose challenge participants for diagnosis of GDM..Diagnosis will be based on 1-hour glucose challenge test results: 1-hour result ≤ 130 mg/dL, the participant will have passed the challenge test. 1-hour result ≥ 130 mg/dL will complete a three-hour 100g glucose tolerance test. If two out of three values are elevated per Carpenter Coustan criteria , the participant will be ...Show More |
ExperimentalCGM screening | Group 2: CGM placement CGM will consist of using the Dexcom G6 Pro device. The device will be placed on the abdomen or the arm.The Dexcom G6/G7 Pro App will be downloaded on the patient's phone. A patient profile will be created on the Dexcom Clarity portal .The patient will receive an email to link their portal to the clinic's portal.The patient will receive a message through Epic electronic medical records to remove the CGM 10 days after...Show More |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Number of Neonates That Show Composite Adverse Neonatal Outcome | Composite adverse neonatal outcome include one or more of the following:
* Large for Gestational Age(LGA) is described as weight over 90th percentile of the expected value according to gestational age (using the nomogram by Duryea EL et al)
* Shoulder Dystocia is defined as the need for any extra maneuvers, other than gentle downward traction of the fetal head to deliver the fetal body after the fetal head has been delivered
* Birth injury: skull, clavicular, humerus fracture, or brachial plexus injury
* Neonatal hypoglycemia: less than 40 mg/dL in the first 24 hours of life and less than 50 mg/dL after or requiring medical therapy
* Respiratory distress is described as the need for at least 4 hours of respiratory support with supplemental oxygen, continuous positive airway pressure, or ventilation at the first 24 hours of life
* Fetal or neonatal death (within 28 days of birth) | From birth to about 28 days of life. |
Number of Neonates That Show Adverse Neonatal Outcome of Large for Gestational Age(LGA) | LGA is described as weight over 90th percentile of the expected value according to gestational age (using the nomogram by Duryea EL et al) | at time of birth |
Number of Neonates That Show Adverse Neonatal Outcome of Shoulder Dystocia | Shoulder dystocia is defined as the need for any extra maneuvers, other than gentle downward traction of the fetal head to deliver the fetal body after the fetal head has been delivered | at time of birth |
Number of Neonates That Show Adverse Neonatal Outcome of Birth Injury | Birth injury: skull, clavicular, humerus fracture, or brachial plexus injury | at time of birth |
Number of Neonates That Show Adverse Neonatal Outcome of Neonatal Hypoglycemia | Neonatal hypoglycemia: less than 40 mg/dL in the first 24 hours of life and less than 50 mg/dL after or requiring medical therapy | from birth to discharge (about 3-15 days) |
Number of Neonates That Show Adverse Neonatal Outcome of Respiratory Distress | Respiratory distress is described as the need for at least 4 hours of respiratory support with supplemental oxygen, continuous positive airway pressure, or ventilation at the first 24 hours of life | from birth to discharge (about 3-15 days) |
Number of Fetal or Neonatal Deaths | within 28 days of birth |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Feasibility as Assessed by the Number of Participants Who Complete the CGM Diagnostic Testing | From enrollment to 6 weeks post partum, on average 21 weeks | |
Number of Women That Use Diabetic Medication During Pregnancy | diabetic medication is described as any glycemic control agent | From enrollment to 6 weeks post partum, on average 21 weeks |
Number of Women That Show Polyhydramnios During Pregnancy Not Related to Known Fetal Anomaly | From enrollment to delivery | |
Number of Women That Have Preterm Birth | Pre term birth is described as delivery less than 37 weeks of gestation | at time of birth |
Number of Women That Undergo Induced Labor | at time of birth | |
Number of Women That Experience Pregnancy Induced Hypertension | From enrollment to 6 weeks post partum, on average 21 weeks | |
Number of Women That Experience Eclampsia: Seizures | From enrollment to 6 weeks post partum, on average 21 weeks | |
Number of Women Admitted Due to Poor Glucose Control | From enrollment up to delivery | |
Number of Women With Primary Cesarean Section | at time of birth | |
Number of Women With Postpartum Hemorrhage: Defined as Greater Then 1000ml | From enrollment to 6 weeks post partum, on average 21 weeks | |
Number of Women With Endometritis | From enrollment to 6 weeks post partum, on average 21 weeks | |
Number of Women With Wound Complications | From enrollment to 6 weeks post partum, on average 21 weeks | |
Number of Women With Diagnosis of Type 2 Diabetes During Postpartum | birth to 6 weeks postpartum | |
Number of Neonates With Apgar Score Less Than 7 | The Apgar score is determined by evaluating the newborn baby on each of five criteria (appearance, pulse, grimace, activity, respiration) on a scale from zero to two, then summing the five values obtained. The total score ranges from zero to 10. A higher score indicates a better outcome. | 5 minutes after birth |
Number of Neonates That Are Admitted to the Neonatal Intensive Care Unit (NICU) | birth to time of discharge from NICU (about 15 days) | |
NICU Length of Stay | birth to time of discharge from NICU (about 15 days) | |
Number of Neonates With Hyperbilirubinemia Requiring Phototherapy | birth to discharge (about 3-15 days) | |
Number of Neonates With Need for Intravenous or Oral Administration Glucose Therapy | birth to discharge (about 3-15 days) | |
Number of Neonates That Are Small for Gestational Age | Small for gestational age, defined as a weight below 10th percentile of the expected value according to gestational age (using the nomogram published by Duryea EL et al) | at time of birth |
Number of Participants Who Breastfed Their Babies | from birth to 6 weeks postpartum | |
Number of Participants Who Formula Fed Their Babies | from birth to 6 weeks postpartum | |
Maximum Bilirubin Level - Neonates | birth to discharge (about 3 -15 days) | |
Cord Arterial pH | at time of birth | |
Number of Neonates With Polycythemia | birth to discharge (about 3 -15 days) | |
Number of Women That Experience Preeclampsia With Severe Features | From enrollment to 6 weeks post partum, on average 21 weeks | |
Number of Women That Experience Super Imposed Preeclampsia | From enrollment to 6 weeks post partum, on average 21 weeks | |
Number of Women With Need for Blood Transfusion | From enrollment to 6 weeks post partum, on average 21 weeks | |
Number of Participants With Ultrasound Diagnosis of Estimated Fetal Weight >90%Ile in the Third Trimester | Third trimester (≥28 weeks gestation through delivery) | |
Number of Women That Experience HELLP Syndrome | HELLP syndrome: a group of symptoms in pregnant women characterized by hemolysis (H), elevated liver enzymes (EL), and/or low platelet (LP) count, assessed according to ACOG guidelines. | From enrollment to 6 weeks post partum, on average 21 weeks |
Cord Venous pH | at time of birth | |
Total Health System Costs for Mothers and Infants | From enrollment to 6 weeks post partum, on average 21 weeks |
Eligibility Criteria
Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
Female
- 24-30 weeks gestation undergoing GDM screening
- Known diagnosis of Type I and II DM
- History of bariatric surgery
- Major fetal anomalies
- Unwilling to use CGM for GDM screening
- Incarcerated subjects
- History of allergic reaction to any of CGM metals or adhesives in contact with the skin
Study Responsible Party
Michal Fishel Bartal, Principal Investigator, Assistant Professor, The University of Texas Health Science Center, Houston
No contact data.
1 Study Locations in 1 Countries
Texas
The University of Texas Health Science Center at Houston, Houston, Texas, 77030, United States